Gonçalves 2019 Mitofit Preprint Arch EA

From Bioblast
Revision as of 08:47, 19 June 2019 by Iglesias-Gonzalez Javier (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Gonçalves 2019 Mitofit Preprint Arch EA

Publications in the MiPMap
Gonçalves Debora F, Courtes AA, Hartmann DD, Carvalho PR, Marques DM, Machado ML, Furtado AV, Soares FA, Dalla Corte CL (2019) Aging effects on mitochondrial control factors in Pink1 knockout Drosophila melanogaster. MitoFit Preprint Arch doi:10.26124/mitofit:ea19.MiPSchool.0002.


MitoFit pdf

Aging effects on mitochondrial control factors in Pink1 knockout Drosophila melanogaster

Goncalves DF, Courtes AA, Hartmann DD, Carvalho PR, Marques DM, Machado ML, Furtado AV, Soares FA, Dalla Corte CL (2019) MitoFit Preprint Arch

Abstract: Version 1 (v1) 2019-06-03 doi:10.26124/mitofit:ea19.MiPSchool.0002

Parkinson disease (PD) is considered the second most common neurodegenerative disorder in the world and is related mainly with aging. PD is characterized by loss of dopaminergic neurons and formation of protein aggregates, such as α-synuclein [1], leading to motor dysfunction, and impairment of cognitive and memory functions [2]. The pathology and symptoms of PD are well described, although its mechanisms and causes remain unclear. One mechanism involved in PD is mitochondrial dysfunction [3]. Mutation in genes involved in mitochondrial quality control, such as PARK2 and Pink1, produce PD symptoms [4]. These genes code for proteins such as PINK1 (PTEN induced kinase 1) that is a serine/threonine kinase involved in mitochondrial network quality control [5]. In this work we evaluated mitochondrial quality control using Pink1 knockout of Drosophila melanogaster in different lifetime.

Keywords: PARK2 & PINK1 Bioblast editor: Iglesias-Gonzalez J


Gonçalves Debora F(1), Courtes AA(1), Hartmann DD(1), Carvalho PR(1), Marques DM(1), Machado ML(1), Furtado AV(1), Soares FA(1), Dalla Corte CL(1,2) - [email protected]

  1. Univ Federal de Santa Maria, Brazil. Biochemistry and molecular biology Dpt.
  2. Univ Federaldo Pampa, Brazil


Goncalves 2019 MitoFit Preprint Arch EA Figure 1.png
Goncalves 2019 MitoFit Preprint Arch EA Figure 2.png


  1. R. Requejo-Aguilar, I. Lopez-Fabuel, E. Fernandez, L.M. Martins, A. Almeida, J.P. Bolaños, PINK1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1., Nat. Commun. 5 (2014) 4514. doi:10.1038/ncomms5514.
  2. C.G. Goetz, The history of Parkinson’s disease: early clinical descriptions and neurological therapies., Cold Spring Harb. Perspect. Med. 1 (2011) a008862. doi:10.1101/cshperspect.a008862.
  3. N. Ammal Kaidery, B. Thomas, Current perspective of mitochondrial biology in Parkinson’s disease, Neurochem. Int. (2018). doi:10.1016/j.neuint.2018.03.001.
  4. H.-L. Wang, A.-H. Chou, A.-S. Wu, S.-Y. Chen, Y.-H. Weng, Y.-C. Kao, T.-H. Yeh, P.-J. Chu, C.-S. Lu, PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons., Biochim. Biophys. Acta. 1812 (2011) 674–84. doi:10.1016/j.bbadis.2011.03.007.
  5. C.A. Gautier, T. Kitada, J. Shen, Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress, Proc. Natl. Acad. Sci. 105 (2008) 11364–11369. doi:10.1073/pnas.0802076105.
  6. D. Pesta, E. Gnaiger, High-Resolution Respirometry: OXPHOS Protocols for Human Cells and Permeabilized Fibers from Small Biopsies of Human Muscle, in: 2012: pp. 25–58. doi:10.1007/978-1-61779-382-0_3.
  7. R. Requejo-Aguilar, J.P. Bolaños, Mitochondrial control of cell bioenergetics in Parkinson’s disease, Free Radic. Biol. Med. 100 (2016) 123–137. doi:10.1016/j.freeradbiomed.2016.04.012.

Preprints for Gentle Science

MitoFit Preprint Arch.png

» MitoFit Preprint Archives - The Open Access preprint server for mitochondrial physiology and bioenergetics

» MitoPedia: Preprints